Please assess the completion status of the following clinical trial:

Trial Title: Study of Chiglitazar Compare With Sitagliptin in Type 2 Diabetes Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Meet the WHO Diagnostic Criteria for Type 2 Diabetes (published on 1999);~2. HbA1c≥ 7.5% and ≤ 10.0% after control of diet and exercises;~3. Male and female,age between 18 and 70 years;~4. BMI between 18.5-35kg/m2;~5. Willing to be assigned to any treatment arm and sign inform consent.~Exclusion Criteria:~1. Type 1 diabetes;~2. Treated by oral or injective antidiabetic drug before screening, including insulin and herb;~3. Fasting plasma glucose \> 13.3 mmol/L (240 mg/dL);~4. Resistant hypertension \[blood pressure above the goal despite adherence to at least 3 optimally dosed antihypertensive medications (including diuretic) of different classes,or blood pressure is controlled to below the goal by at least different classes of drugs\];~5. Plasma triglyceride \> 500 mg/dL (5.65 mmol/L);~6. Is treating by fibrates;~7. History of diabetic ketoacidosis,diabetic hyperglycemic hyperosmolar syndrome,lactic acidosis, diabetic hypoglycemia; or is currently combined with retinopathy, diabetic nephropathy and diabetic neuropathy;~8. Had transient ischemic attack,cerebrovascular accident or unstable angina in the past 6 months;~9. History of myocardial infarction or had conducted coronary angioplasty or coronary artery bypass graft surgery;~10. Had or is having pancreatic diseases;~11. Heart failure (NYHA classification Stage III or IV), or left ventricular hypertrophy indicated by ECG;~12. Hepatic diseases such as hepatocirrhosis, active hepatitis,aspartate aminotransferase or alanine aminotransferase \> 2.5 fold of the upper limit of the normal range;~13. Kidney diseases or serum creatinine exceed the normal range: male \> 133 μmol/L or female \>108 μmol/L;~14. Had malignancy in the past 5 years, not including basal cell carcinoma;~15. Had or is currently receiving treatment that can alter blood glucose metabolism, including but not limited to diuretic,hormone (corticotropin or steroids),beta blockers;~16. Have the diseases that can alter blood glucose metabolism, including but not limited to active hepatitis, hyperthyroidism,or adrenal tumors;~17. Edema with unknown reason;~18. Alcohol or drug addiction;~19. Had participated other drugs' clinical trials in the 3 months before screening;~20. Pregnant or lactic women; or women of childbearing age who are not able to or is not willing to conduct contraception;~21. Any condition that make investigator consider the subject is not suitable to participate the trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): Patients administrate Chiglitazar 32mg once daily for 24 weeks
- Arm 2 (Type: EXPERIMENTAL): Patients administrate Chiglitazar 48mg once daily for 24 weeks
- Arm 3 (Type: ACTIVE_COMPARATOR): Patients administrate Sitagliptin 100mg once daily for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).